Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26)
| Autor: | María-José Camarasa, Carlos García-Aparicio, Alberto Diez-Torrubia, Sonsoles Velázquez, Anne-Marie Lambeir, Jan Balzarini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Serum
Stereochemistry Dipeptidyl Peptidase 4 Dipeptidyl peptidase Cell Line Virology Humans Prodrugs Spiro Compounds Bovine serum albumin Uridine Pharmacology chemistry.chemical_classification Oligopeptide biology Tetrapeptide Chemistry Prodrug Amino acid Enzyme Solubility Cell culture HIV-1 biology.protein Oligopeptides Thymidine |
| Zdroj: | Antiviral research |
| ISSN: | 0166-3542 |
| Popis: | A novel prodrug approach has been evaluated using the anti-HIV-active TSAO molecule as the prototype drug to prove the kinetics with purified enzyme and the principles of conversion to the parent compound in sera and cell culture. When a variety of tetrapeptidyl amide prodrugs of NAP-TSAO were synthesized and exposed to purified dipeptidyl-peptidase IV (DPPIV/CD26) as well as human and bovine sera, they are converted to the parent NAP-TSAO drug in two successive steps by both purified CD26 and human and bovine serum. The efficiency of conversion strongly depends on the nature of the amino acid that has to be cleaved-off from the prodrug molecule. The tetrapeptidyl prodrug 20 showed a more than 10-fold improved water-solubility in comparison to that of the parent compound NAP-TSAO. The antiviral activity of the prototype NAP-TSAO could also be modulated by introducing different tetrapeptide moieties on the molecule resulting, in some cases, in a superior antiviral potential in cell culture than the parent drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect